Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 12, 2006, Pages 1789-1793

  Yang, Sheng Shun ^a,b   Fu, Lin Shien ^a   Chang, Chi Sen ^a   Yeh, Hong Zen ^a   Chen, Gran Hum ^a   Kao, Jia Horng ^c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chronic hepatitis; Hepatitis C virus; Interferon; Lymphocytes; Ribavirin; sCD26; sCD30; Th1 Th2 response

Indexed keywords

ALPHA2B INTERFERON; CD30 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; GENOTYPE; HELPER CELL; HEPATITIS C; HOST CELL; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIROLOGY;

EID: 33750452743     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04677.x     Document Type: Article

References (29)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36 (5 Suppl. 1): S21-9.
2. Hegen M, Niedobitek G, Klein CE, Stein H, Fleisher B. The triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J. Immunol. 1990; 144: 2908-14.
3. Willheim M, Ebner C, Baier K et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T (H1) subsets. J. Allergy Clin. Immunol. 1997; 100: 348-55.
4. Smith CA, Davis T, Anderson D et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990; 248: 1019-23.
5. Del Prete G, De Carli M, Almerigogna F et al. Preferential expression of CD30 by human CD4 T cells producing Th2-type cytokines. FASEB J. 1995; 9: 81-6.
6. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 1995; 16: 34-8.
7. Hoshimoto K, Ohta N, Ohkura T, Inaba N. Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1/Th2 balance? Gynecol. Obstet. Invest. 2000; 50: 260-63.
8. Schonermarck U, Csernok E, Trabandt A, Hansen H, Gross WL. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin. Exp. Rheumatol. 2000; 18: 457-63.
9. Gonzalez-Peralta RP, Davis GL, Lau JY. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J. Hepatol. 1994; 21: 255-9.
10. Tsai SL, Chen PJ, Hwang LH et al. Immune response to a hepatitis C virus nonstructural protein in chronic hepatitis C virus infection. J. Hepatol. 1994; 21: 403-11.
11. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implication for hepatitis C virus chronicity. Hepatology 1997; 25: 449-58.
12. Ulsenheimer A, Gerlach JT, Gruener NH et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003; 37: 1189-98.
13. Sreenarasimhaiah J, Jaramillo A, Crippin J, Lisker-Melman M, Chapman WC, Mohanakumar T. Concomitant augmentation of type I CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum. Immunol. 2003; 64: 497-504.
14. Lai MY, Kao JH, Yang PM et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
15. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 1485-92.
16. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
17. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
18. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
19. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-82.
20. Ohno O, Mizokami M, Wu RR et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J. Clin. Microbiol. 1997; 35: 201-7.
21. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin. Liver Dis. 2000; 20: 127-41.
22. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J. Immunol. 1997; 159: 1012-18.
23. Lee S, Macquillan GC, Keane NM et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol. Cell Biol. 2002; 80: 391-7.
24. Keane NM, Price P, Lee S, Stone SF, French MA. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin. Exp. Immunol. 2001; 126: 111-16.
25. Masaki N, Fukushima S, Hayashi S. Lower Th-1/Th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig. Dis. Sci. 2002; 47: 2163-9.
26. Abayli B, Canataroglu A, Akkiz H. Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection. Turk. J. Gastroenterol. 2003; 14: 7-11.
27. Keane NM, Price P, Lee S, Stone SF, French MA. An evaluation of serum soluble CD30 levels and serum CD26 (DPP IV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin. Exp. Immunol. 2001; 26: 111-16.
28. Firneisz G, Lakatos PL, Szalay F, Hungarian Viral Hepatitis Study Group. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand. J. Gastroenterol. 2001; 36: 877-80.
29. Foschi FG, Gramenzi A, Castelli E et al. Soluble CD30 serum level in HCV-positive chronic active hepatitis: a surrogate marker of disease activity? Cytokine 2000; 12: 815-18.